American Association for Cancer Research
15357163mct200883-sup-253789_2_supp_7129172_qtttry.pdf (135.77 kB)

Supplementary Fig 1 from The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells

Download (135.77 kB)
journal contribution
posted on 2023-04-03, 18:40 authored by Hong Shik Yun, Jennifer Lee, Whoon Jong Kil, Tamalee R. Kramp, Philip J. Tofilon, Kevin Camphausen

suppl fig 1


NCI intramural program



AZD0530, a potent small-molecule inhibitor of the Src kinase family, is an anticancer drug used in the treatment of various cancers. In the case of glioblastoma (GBM), where resistance to radiotherapy frequently occurs, Src kinase is known as one of the molecules responsible for imparting radioresistance to GBM. Thus, we evaluated the effect of AZD0530 on the radiosensitivity of human GBM cells and human glioblastoma stem-like cells (GSCs). We show that Src activity of GBM and GSC is increased by radiation and inhibited by AZD0530, and using clonogenic assays, AZD0530 enhances the radiosensitivity of GBM and GSCs. Also, AZD0530 induced a prolongation of radiation-induced γH2AX without specific cell cycle and mitotic index changes, suggesting that AZD0530-induced radiosensitization in GBM cells and GSCs results from the inhibition of DNA repair. In addition, AZD0530 was shown to inhibit the radiation-induced EGFR/PI3K/AKT pathway, which is known to promote and regulate radioresistance and survival of GBM cells by radiation. Finally, mice bearing orthotopic xenografts initiated from GBM cells were then used to evaluate the in vivo response to AZD0530 and radiation. The combination of AZD0530 and radiation showed the longest median survival compared with any single modality. Thus, these results show that AZD0530 enhances the radiosensitivity of GBM cells and GSCs and suggest the possibility of AZD0530 as a clinical radiosensitizer for treatment of GBM.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager